2023

Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial
Flaadt T, Ladenstein R, Ebinger M, Lode H, Arnardóttir H, Poetschger U, Schwinger W, Meisel R, Schuster F, Döring M, Ambros P, Queudeville M, Fuchs J, Warmann S, Schäfer J, Seitz C, Schlegel P, Brecht I, Holzer U, Feuchtinger T, Simon T, Schulte J, Eggert A, Teltschik H, Illhardt T, Handgretinger R, Lang P
J CLIN ONCOL. 2023;41(17):3135-3148.

Evaluating the safety of perioperative dexamethasone treatment: A retrospective analysis of a single center pediatric low-grade glioma cohort
Gorodezki D, Zipfel J, Queudeville M, Holzer U, Bevot A, Schittenhelm J, Nägele T, Schuhmann M, Ebinger M
INT J CANCER. 2023;152(9):1875-1883.

Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia
Queudeville M, Stein A, Locatelli F, Ebinger M, Handgretinger R, Gökbuget N, Gore L, Zeng Y, Gokani P, Zugmaier G, Kantarjian H
CANCER-AM CANCER SOC. 2023;129(9):1384-1393.

Th1 cytokines in pediatric acute lymphoblastic leukemia
Schober S, Rottenberger J, Hilz J, Schmid E, Ebinger M, Feuchtinger T, Handgretinger R, Lang P, Queudeville M
CANCER IMMUNOL IMMUN. 2023;72(11):3621-3634.

Letzte Aktualisierung aus dem FIS: 30.10.2024 - 23:34 Uhr